Loading...
•
Jun 30, 2024
2Seventy Bio Q2 2024 Earnings Report
Reported financial results and operational progress for the second quarter of 2024.
Key Takeaways
2seventy bio reported a transformative quarter with a focus on Abecma, highlighted by $54 million in U.S. commercial revenue, a 43% reduction in operating expenses, and a strengthened balance sheet. The company completed the sale of its oncology R&D business to Regeneron and its Hemophilia A program to Novo Nordisk, positioning it to achieve profitability by the end of 2025.
Abecma generated $54 million in U.S. commercial revenue with growth in demand.
Completed sale of Hemophilia A and gene editing technology to Novo Nordisk for up to $40 million.
Operating expenses decreased by 43% due to the sale of R&D business to Regeneron.
Ended the quarter with approximately $202 million in cash, cash equivalents, and marketable securities, extending cash runway beyond 2027.
2Seventy Bio
2Seventy Bio
2Seventy Bio Revenue by Segment
Revenue by Segment
Service Revenue
CapyFin.comCollaborative arrangement Revenue
CapyFin.com Forward Guidance
2seventy bio is focused on commercial growth of Abecma, supported by a streamlined cost structure and a strengthened balance sheet, with the goal of achieving quarterly profitability by the end of 2025.
Positive Outlook
- Continued execution of the third line launch in the second half of 2024.
- Anticipated continued growth for Abecma.
- Strategic realignment to focus on Abecma development and commercialization.
- Expected cost savings from the sale of oncology and autoimmune R&D programs.
- Strengthened balance sheet through recent transactions.
Challenges Ahead
- Risk that Abecma will not be as commercially successful as anticipated.
- Risk that strategic realignment may not be as successful as anticipated.
- Risk of failure to achieve anticipated cost savings.
- Risk of disruptions in business that could make it difficult to achieve strategic objectives.
- Risk of inability to manage operating expenses or cash use for operations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income